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Summary
The role of chromatin structure in lineage commitment of multipotent hematopoietic progenitors 
(HPCs) is presently unclear. We show here that CD34+ HPCs possess a post-replicative chromatin 
globally devoid of the repressive histone mark H3K27me3. This H3K27-unmodified chromatin is 
required for recruitment of lineage-determining transcription factors (TFs) C/EBPα, PU.1 and 
GATA-1 to DNA just after DNA replication upon cytokine-induced myeloid or erythroid 
commitment. Blocking DNA replication or increasing H3K27me3 levels prevents recruitment of 
these TFs to DNA and suppresses cytokine-induced erythroid or myeloid differentiation. However, 
H3K27me3 is rapidly associated with nascent DNA in more primitive human and murine HPCs. 
Treatment of these cells with instructive cytokines leads to a significant delay in accumulation of 
H3K27me3 in nascent chromatin due to activity of the H3K27me3 demethylase UTX. Thus, HPCs 
utilize special mechanisms of chromatin modification for recruitment of specific TFs to DNA 
during early stages of lineage specification.
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Introduction
The process of hematopoiesis is regulated by a network of transcription factors (TFs) acting 
cooperatively or antagonistically on multipotent or lineage-restricted hematopoietic 
progenitors/precursors (Friedman, 2007; Orkin and Zon, 2008). A critical step in 
differentiation of hematopoietic stem cells (HSCs) is the commitment of multipotent 
progenitors to lineage-restricted progenitors. The prevailing explanation for lineage 
commitment is that it depends on stochastic fluctuation in the levels of competing lineage-
determining TFs that activate a lineage-specific gene expression program while suppressing 
those leading to alternative choices (Cantor and Orkin, 2001; Chang et al., 2008; Graf and 
Enver, 2009; Orkin, 2000; Till et al., 1964).
However, recent studies support an “instructive” model whereby lineage-specific cytokines 
(e.g., Granulocyte-colony stimulating factor (G-CSF), Macrophage-colony stimulating factor 
(M-CSF) or Erythropoietin (EPO)) act on multipotent progenitors to activate lineage-
specific master TFs and promote the expansion of the myeloid or the erythroid lineage 
(Grover et al., 2014; Mossadegh-Keller et al., 2013; Rieger et al., 2009). On the other hand, 
single cell transcription profiling of primitive hematopoietic progenitors purified based on 
the expression of surface markers commonly used to define a “multipotent state” has 
revealed that truly multipotent progenitors may not exist and that these cells are highly 
heterogeneous and may be already committed to a specific lineage (Notta et al., 2016; Paul 
et al., 2015; Perie et al., 2015). Collectively, these findings raise the possibility that both 
“stochastic” and “instructive” mechanisms contribute to lineage specification and that 
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“instructive” cytokines function in this process earlier than previously thought. Specification 
of myeloid cell fate requires the TFs PU.1 and C/EBPα, but macrophage versus granulocytic 
differentiation depends on the relative levels of PU.1 or C/EBPα, respectively (Dahl et al., 
2003; Iwasaki et al., 2006; Laslo et al., 2006). EPO has an instructive role for erythroid 
commitment of stem cell-enriched cell subsets, a process that is, at least in part, GATA-1-
dependent (Cui et al., 2009; Grover et al., 2014).
While C/EBPα, PU.1 or GATA-1 can promote unilineage differentiation by inducing new 
transcriptional programs, it remains unclear how these TFs cause changes in the existing 
epigenetic maintenance system. Upon EPO-induced erythroid differentiation of the 
multipotent CD133+CD34+ HPCs global changes in gene expression are in general 
correlated with the changes in association of the H3K4me3 or the H3K27me3 positive or 
negative histone marks respectively, although some “bivalent” genes lost or retained both 
marks (Cui et al., 2009). These changes in chromatin marks and gene expression profiles 
were detected in cells induced to erythroid differentiation for 9–11 days (Cui et al., 2009), 
suggesting that they may not reflect “commitment” to differentiation toward a specific 
lineage which is likely to occur much earlier. The dynamics of certain chromatin 
modifications was also globally examined in purified subsets representing distinct stages of 
murine hematopoietic differentiation (Lara-Astiaso et al., 2014). The results of this analysis 
are consistent with the existence of a transcription factor network that may control 
chromatin dynamics and lineage specification.
However, these studies are mostly correlative and do not provide a mechanistic explanation 
for how changes in transcriptional programs and chromatin structure occur. An essential 
issue is how newly induced TFs overcome the existing chromatin-based barrier when they 
are recruited to new target genes. It is also not clear whether chromatin marks play any role 
in allowing the access of lineage-determining TFs to the regulatory regions of the genes 
essential for differentiation, and whether chromatin changes occur before or after changes in 
the transcriptional programs. Thus, at present we only know the end results of lineage 
specification, but there is insufficient information on the molecular mechanisms that allow 
these changes during the early stages of lineage commitment. Knowledge of these 
mechanisms is essential in order to control lineage specification and may be important in 
understanding the mechanisms responsible for the differentiation arrest of leukemic cells.
In our study, we examined the assembly of chromatin in vivo at single-cell and gene-specific 
levels following DNA replication. We show that CD34+ HPCs possess a post-replicative 
chromatin globally devoid of the repressive histone mark H3K27me3. This type of 
chromatin is required for recruitment of C/EBPα, PU.1 and GATA-1 to DNA just after DNA 
replication upon treatment with instructive cytokines to induce erythroid or myeloid 
commitment. Blocking DNA replication or increasing H3K27me3 levels prevents 
recruitment of these TFs to DNA and suppresses cytokine-induced erythroid or myeloid 
differentiation. By contrast, H3K27me3 is rapidly associated with nascent DNA in primitive 
CD34+CD38− HPCs and treatment of these cells with instructive cytokines leads to a period 
of de-condensed, H3K27me3-unmodified nascent chromatin due to increase of the 
H3K27me3 demethylase UTX. These studies suggest that HPCs utilize special mechanisms 
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of chromatin alteration for recruitment of specific TFs to DNA during initial stages of 
differentiation.
Results
Dynamics of H3K27me3 chromatin during lineage specification of multipotent 
hematopoietic progenitors
Our previous studies suggested that accumulation of major histone modifications, including 
H3K27me3, following DNA replication is delayed by at least 1 hr in cells of developing 
Drosophila embryos (Petruk et al., 2012). This suggests that modified histones do not 
directly carry epigenetic information, and implies that post-replicative chromatin may 
transiently consist of nucleosomes lacking H3K27me3 marks, which were not detected 
previously in bulk chromatin (Petruk et al., 2012). Since the absence of repressive 
H3K27me3 correlates with low density of nucleosomes (Bell et al., 2010; Shlyueva et al., 
2014; Yuan et al., 2012), such unmodified histones may create a very de-condensed 
conformation of post-replicative chromatin. We hypothesize that this unusual H3K27me3-
unmodified post-replicative chromatin may be essential during early stages of differentiation 
to create more favorable conditions for binding of newly induced lineage-determining TFs.
First, we examined whether chromatin lacking H3K27me3 is a common feature of human 
HPCs. We used the “Chromatin Assembly Assay (CAA)” (Petruk et al., 2012), to examine 
the rate of accumulation of H3K27me3 in human cord blood and G-CSF-mobilized CD34+ 
progenitor cells. DNA in proliferating CD34+ cells was pulse-labeled with EdU, which was 
then conjugated with biotin, and the proximity of H3K27me3 to nascent DNA was assessed 
by the Proximity Ligation Assay (PLA, Olink) using antibodies to biotin and H3K27me3. 
Following CAA, cells were immunostained with EdU and DAPI to assess the specificity of 
the assay. We found that in CD34+ cells H3K27me3 accumulates significantly at nascent 
DNA only at around 2 hr following DNA replication (Figure 1A).
Then, we examined whether the accumulation of post-replicative H3K27me3 undergoes 
changes during lineage specification of HPCs. Cells were induced toward granulocytic or 
macrophage differentiation by treatment with G-CSF or M-CSF, respectively, and 
accumulation of H3K27me3 on nascent DNA was analyzed after 15 min of EdU 
incorporation. No H3K27me3 was detected on 15 min EdU-labeled nascent DNA at 6 hr and 
12 hr after G-CSF or M-CSF treatment. However, we detected significant accumulation of 
H3K27me3 on 15 min EdU-labeled nascent DNA at 24 hr after induction with each cytokine 
(Figure 1B). Thus, irrespective of lineage choice, the H3K27me3-unmodified post-
replicative chromatin structure of HPCs persists for at least 12 hr following exposure to 
instructive cytokines. The post-replicative structure of chromatin may become more compact 
1 day into HPC differentiation.
Lineage-determining transcription factors bind to post-replicative H3K27me3-unmodified 
chromatin upon cytokine-induced lineage commitment
Induction with ‘instructive’ cytokines leads to expression of key TFs that specifically change 
the transcriptional landscape of differentiating HPCs. It is not known whether there is a 
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specific mechanism that allows these TFs to bind to DNA during cell differentiation. 
Previous EMSA analyses showed that C/EBPα is associated with promoters of target genes 
after 3 days of G-CSF-induced differentiation of myeloid precursor cells (Iida et al., 2008). 
To further investigate this, we used the CAA to examine the association of C/EBPα, PU.1 
and GATA-1 with DNA following induction with G-CSF, M-CSF and EPO, respectively, of 
cord blood or G-CSF-mobilized peripheral blood CD34+ cells. As expected, cytokine 
treatment induced a decrease in CD34 positivity first detected at 72 hrs and the simultaneous 
appearance of lineage-specific differentiation markers (Figure 2A and Figure S1). C/EBPα 
and PU.1 are first detected on the 1 hr EdU-labeled nascent DNA at 6 hr following treatment 
with G-CSF and M-CSF, respectively, while GATA-1 is detected at 12 hr following 
induction with EPO (Figure 2B). Thus, irrespective of the induced differentiation program, 
specific TFs are recruited to DNA at 6–12 hr following treatment with lineage-determining 
cytokines, much earlier than previously thought. Importantly, the time of recruitment is 
within the period in which cytokine-treated HPCs carry the H3K27me3-unmodified post-
replicative chromatin.
These results are consistent with our hypothesis that recruitment of key lineage-determining 
TFs to DNA may be facilitated by the low-nucleosome density of post-replicative chromatin 
devoid of H3K27me3. This state of histone H3K27 modification may result from the 
activities of H3K27me3-specific homologous histone demethylases (KDMs) UTX and 
JMJD3. To examine this, we inhibited the activities of these KDMs by treatment with 
GSKJ4, a small molecule inhibitor of these enzymes (Kruidenier et al., 2012). Then, cord 
blood CD34+ cells were induced for 12 hr to myeloid or erythroid differentiation with G-
CSF or M-CSF, or EPO, respectively, and accumulation of H3K27me3 was analyzed by 
CAA on nascent DNA labeled with EdU for 15 min. Similar to previous results with G-CSF 
and M-CSF (Figure 1), we did not detect H3K27me3 on 15 min EdU-labeled nascent DNA 
following 12 hr induction with EPO (Figure 3A, upper panels). Treatment of cells with 
GSKJ4 leads to significant accumulation of H3K27me3 on nascent DNA labeled with EdU 
for 15 min following 12 hr induction of these cells with all three lineage-determining 
cytokines (Figure 3A, lower panels). Then, we asked whether faster accumulation of post-
replicative H3K27me3 affects recruitment of induced TFs in these cell lineages. The strong 
recruitment of C/EBPα, PU.1 and GATA-1, detected at 12 hr following induction with the 
corresponding cytokine (Figure 2 and 3A, upper panels), was completely blocked by 
treatment with GSKJ4 (Figure 3A, lower panels). This suggests that the H3K27me3-
unmodified post-replicative chromatin is favorable for recruitment of C/EBPα, PU.1 and 
GATA-1 to their DNA binding sites.
By contrast, maintaining H3K27me3 accumulated on nascent chromatin may prevent 
association of key lineage-inducing TFs to DNA, leading to decreased induction of the gene 
targets of these TFs, and may ultimately result in a block of lineage specification.
In line with this, expression of GATA-1 was not affected by GSKJ4 treatment of EPO-
stimulated CD34+ cells (Figure 3B); by contrast, inhibiting GATA-1 binding to DNA 
(Figure 3A, right panel) led to a marked decrease in the expression of GATA-1-regulated 
genes (Welch et al., 2004) and a complete block of EPO-induced differentiation revealed by 
loss of erythroid marker expression (Figures 3C, D). Likewise, treatment with GSKJ4 had 
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no effect on G-CSF-induced C/EBPα expression but suppressed cytokine-induced myeloid 
differentiation of mobilized CD34+ cells, as indicated by its ability to block the increase in 
the expression of several C/EBPα-regulated genes (Figure S2A). Moreover, compared to 
treatment with G-CSF only, co-treatment with GSKJ4 resulted in a less differentiated 
phenotype revealed by the marked decrease in the proportion of cells co-expressing the 
CD33 and the CD15 differentiation antigens (27.5 vs 53.2%) (Figure S2B). Of interest, at 
the 72 hr time point chosen for the analysis of erythroid differentiation markers, CD34 
positivity was essentially identical in cells treated with EPO only or with GSKJ4 and EPO 
(Figure S3). Thus, the H3K27me3 unmodified structure of nascent chromatin is essential for 
lineage specification of HPCs.
C/EBPα is recruited to post-replicative chromatin in the S phase of the cell cycle
It is not well established when lineage-specific TFs are recruited to DNA in undifferentiated 
cells; while some studies propose that this occurs during the G1 phase (Kapinas et al., 2013; 
Murray and Kirschner, 1989; Singh and Dalton, 2009), other studies dispute this idea 
(Filipczyk et al., 2007; Jonk et al., 1992; Li et al., 2012; Mummery et al., 1987). To examine 
this, CD34+ cells were labeled with EdU and then treated with G-CSF for 24 hrs. This 
allows detection of C/EBPα on labeled DNA (Figure 4A, left). However, blocking S phase 
entry in these cells by treatment with thymidine (Fig. 4B, left) prevented the accumulation of 
C/EBPα on EdU-labeled DNA (Fig. 4A, 0 hr). Release from thymidine block for 2 and 4 hr 
allows significant re-initiation of DNA replication (Figure 4B, middle and right), and leads 
to efficient accumulation of C/EBPα on nascent DNA (Figure 4A, 2 and 4 hr). These 
findings support our hypothesis that the initial association of TFs with DNA following 
cytokine treatment occurs primarily during early post-replicative periods in S phase.
Accumulation of H3K27me3-modified chromatin in primitive HPCs
To assess whether the H3K27me3-unmodified chromatin also exists in more primitive 
HPCs, we examined the loading of H3K27me3 on nascent DNA in the CD90+ 
subpopulation of CD34+ cells. Surprisingly, CD90+ cells exhibited high accumulation of 
H3K27me3 on DNA labeled with EdU for only 15 min (Figure 5A). Since most 
CD34+CD90+ cells are contained within the CD34+CD38− subset, we confirmed this fast 
mode of accumulation of H3K27me3 in uninduced CD34+CD38− cells (Figure 5B). 
However, 12 h induction of CD34+CD38− cells with G-CSF or M-CSF led to slow 
accumulation of post-replicative H3K27me3 (Figure 5B). Further treatment for 24 h restored 
fast accumulation of post-replicative H3K27me3. This suggests that compared to 
CD34+cells most of which carry H3K27me3-unmodified post-replicative chromatin, 
H3K27me3-containing chromatin forms very fast after DNA replication in the more 
primitive CD34+CD90+ and CD34+CD38− subsets. Induction with cytokines slows post-
replicative accumulation of H3K27me3, making it similar to that of bulk CD34+ cells. 
Similar to CD34+ cells, further differentiation accelerates accumulation of post-replicative 
H3K27me3 in both types of cells (Figures 1B and 5A). The differences in the initial rate of 
accumulation of post-replicative H3K27me3 between CD34+, CD34+CD38−, and 
CD34+CD90+ cells may be explained by the fact that a significant proportion of bulk 
CD34+ cells likely consists of progenitors with the molecular profile of cells committed to a 
specific lineage but unable to further differentiate in the absence of instructive cytokines. 
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Instead, the H3K27me3-modified chromatin of more primitive CD34+CD38− and 
CD34+CD90+ progenitors may reflect the undifferentiated status of hematopoietic stem 
cells (HSCs) and, upon cytokine treatment, exhibit significant changes in the rate of 
accumulation of H3K27me3 after DNA replication. Similar to that detected in bulk CD34+ 
cells (Figure 2B), G-CSF treatment of CD34+CD38− cells promotes the accumulation of the 
lineage-determining TF C/EBPα on nascent DNA (Figure S4).
We also assessed the loading of H3K27me3 on nascent DNA of primitive Lin-Sca-1+Kit+ 
mouse HPCs. Like human CD34+CD38− cells, these cells exhibited high accumulation of 
H3K27me3 on DNA labeled with EdU for only 15 min (Figure S5); moreover, treatment of 
Lin-Sca-1+Kit+ cells with recombinant murine G-CSF for 4 hr induced a state of globally 
de-condensed, H3K27me3-unmodified nascent chromatin. However, an 8 hr treatment of 
these cells with G-CSF was sufficient to induce the rapid accumulation of H3K27me3 on 
nascent DNA. Together, these data indicate that accumulation of H3K27me3 on nascent 
DNA is similar in primitive human and mouse HPCs, although in the latter cells the kinetics 
appears to be somewhat faster.
Accumulation of H3K27me3 is delayed on nascent chromatin of repressed genes
Our results suggest that following induction with cytokines accumulation of H3K27me3 is 
globally delayed following DNA replication. This implies that accumulation of H3K27me3 
is delayed in regulatory regions of repressed genes that contain H3K27me3 during 
transcriptional interphases. To examine this, we analyzed the kinetics of accumulation of 
H3K27me3 on nascent DNA at the promoters of several repressed genes by re-ChIP assays 
(Francis et al., 2009; Petruk et al., 2012). Since this type of analysis requires approximately 
107 cells per each sample it is not feasible to use purified CD34+CD38− cells in these 
assays. Thus, we used batches of CD34+ cells which contain significant proportion of 
CD38− cells. DNA of uninduced CD34+ cells and CD34+ cells induced with EPO was 
labeled with BrdU for 15 min or for 15 min followed by a chase to 2 hr. Cells were induced 
with EPO for 24 hrs since induction with this cytokine leads to a longer period of delayed 
accumulation of H3K27me3 on nascent DNA than after induction with G-CSF (not shown). 
Chromatin was first immunoprecipitated with antibody to H3K27me3, and in the next step 
the purified DNA was immunoprecipitated with antibody to BrdU. ChIP assays at the first 
immunoprecipitation step demonstrate that four examined genes contain similar amounts of 
H3K27me3 at their promoters before and after EPO induction (Figure 6A), confirming that 
they remain repressed during erythroid differentiation (Cui et al., 2009). In re-ChIP assays 
we detected significant accumulation of H3K27me3 on 15 min BrdU-labeled DNA (Figure 
6B), suggesting a fast mode of accumulation of H3K27me3 characteristic for early 
progenitor cells (Figure 5). Accumulation of H3K27me3 is significantly delayed at the 
promoters of all repressed genes on 15 min of BrdU labeled DNA following induction with 
EPO (Figure 6B). These results confirm at a gene level that accumulation of H3K27me3 on 
nascent DNA is delayed following induction of differentiation of HPCs.
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Cytokine treatment leads to induction of H3K27me3 KDMs UTX and JMJD3 in primitive 
HPCs
The observed differences in the rate of accumulation of H3K27me3 in CD34+CD38− cells 
may depend on changes in the amounts or the activities of the H3K27-specific methylating 
and de-methylating enzymes, such as KMT EZH2 and KDM UTX, respectively. Thus, we 
examined the presence of these enzymes on DNA following DNA replication. Similar 
amounts of the KMT EZH2 were detected in uninduced CD34+CD38− cells, and in the 
same cells induced for 12 hr to myeloid differentiation by G-CSF or M-CSF treatment 
(Figure 7A). However, UTX was not detected on DNA in untreated CD34+CD38− cells, but 
was detected on DNA of these cells 12 hr following induction with each cytokine (Figure 
7A). These results were confirmed by several independent assays. Western blot analysis 
revealed an increase in the UTX protein in G-CSF- or M-CSF-treated (12 hr) CD34+CD38− 
whereas UTX levels did not change after cytokine treatment of the less primitive 
CD34+CD38+ progenitors (Figure 7B); compared to high amounts of EZH2 in all CD34+ 
cells, UTX was barely detectable by immunofluorescence (Figure 7C), or by CAA on 1 hr 
EdU-labeled DNA (Fig. 7D) in the nuclei of more primitive CD90+ cells. Likewise, using 
CAA we detected low amounts of the homologous H3K27me3 KDM JMJD3 on DNA of the 
CD90+ cells, and an increase in this protein in the CD90− cells (Figure 7D). Thus, a 12 hr 
cytokine treatment of primitive HPCs leads to induction of the KDMs UTX and JMJD3 
proteins and their further accumulation on DNA. This may explain the switch detected in 
these cells from the fast to the slow mode of accumulation of post-replicative H3K27me3 
after DNA replication (Figure 5B).
Discussion
Cytokine-induced lineage specification of CD34+ HPCs involves the recruitment of lineage-
determining TFs (e.g., GATA-1 or C/EBPα) to the regulatory regions of differentiation-
related genes and is accompanied by complex changes in transcriptional programs and 
chromatin structure (e.g., patterns of H3K4me3 and H3K27me3 histone marks) (Cui et al., 
2009; Lara-Astiaso et al., 2014; Mercer et al., 2011; Wei et al., 2009). However, it is not 
known whether binding of TFs to new target genes is a regulated process, and whether it is 
affected by histone modifications and the structure of chromatin. Thus, we have a very 
limited view of the molecular mechanisms regulating a switch in transcriptional and 
epigenetic programs in dividing HPCs as these cells undergo lineage specification.
In this study, we uncovered a chromatin-based molecular mechanism of HPCs 
differentiation towards a specific lineage. The H3K27me3 mark rapidly associates with 
nascent DNA in primitive human CD34+CD38− cells (see model in Figure 7E) and mouse 
Lin-Sca-1+Kit+ cells. Upon induction with instructive cytokines, the global accumulation of 
H3K27me3 on nascent DNA is significantly delayed. In line with this, accumulation of 
H3K27me3 in nascent chromatin is also globally delayed in the more differentiated 
CD34+CD38+ HPCs. Our data suggest that transition from a more compact, H3K27me3-
modified, to a more de-condensed, H3K27me3-unmodified chromatin structure, may be 
explained by the induction of H3K27me3 KDMs UTX and JMJD3 that may efficiently de-
methylate this residue.
Petruk et al. Page 8
Cell Rep. Author manuscript; available in PMC 2017 April 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Once established, the H3K27-unmodified chromatin exists for a short period of time at very 
early stages of differentiation. During this period, cytokines also induce expression of 
lineage-specific TFs that quickly associate with DNA (Figure 7E). The transient H3K27-
unmodified chromatin state is essential for the initial association of these TFs with nascent 
DNA that occurs at early stages of DNA replication. Remarkably, maintaining the 
H3K27me3 repressive mark on nascent chromatin of CD34+ HPCs by pharmacological 
inhibition of the H3K27me3 demethylases blocks the association of lineage-determining 
TFs to DNA and suppresses cytokine-induced erythroid or myeloid differentiation (Figure 3 
and Figure S2). Consistent with these findings, conditional knockout of UTX in female mice 
induces marked depletion of erythroid progenitors in the bone marrow and of erythrocytes in 
the peripheral blood, in addition to profound thrombocytopenia and relative leukocytopenia 
(Thieme et al., 2013).
Fast accumulation of the H3K27me3 mark on nascent DNA resumes once CD34+ HPCs 
became committed to a single lineage (Figure 7E); this process may be designed to ensure 
that uni-lineage committed progenitors complete their differentiation program by hindering 
DNA binding of unwanted TFs that may antagonize the effect of the lineage-determining TF 
or cooperatively promote differentiation along a closely related lineage (Friedman, 2007).
The lineage-determining TFs analyzed in this work belong to the class of pioneer factors 
(Iwafuchi-Doi and Zaret, 2014; Zaret and Carroll, 2011) that are able to overcome the 
barrier of chromatin, and to bind to the so-called L-type chromatin which contains 
nucleosomes without many activating or repressive marks including H3K27me3 and to 
facilitate binding of other essential TFs (Iwafuchi-Doi and Zaret, 2016). The pioneer 
property of these TFs was demonstrated mostly during reprogramming of differentiated cells 
following ectopic expression of these proteins (Di Stefano et al., 2014; Feng et al., 2008; 
Heinz et al., 2010; Kulessa et al., 1995; Xie et al., 2004). However, actively repressed 
chromatin (R-type), which includes genes marked by H3K27me3, is not accessible to any 
TF, including pioneer factors (Iwafuchi-Doi and Zaret, 2016).
Our work uncovers a chromatin-based mechanism of recruitment to DNA of lineage-
determining TFs induced at physiological levels by cytokines during differentiation of 
hematopoietic progenitor cell subsets. Based on this model, lineage-determining TFs do not 
need to overcome the chromatin barrier as proposed for pioneer factors on L-type chromatin, 
but gain access to their specific binding sites on a transiently “open” chromatin of nascent 
DNA. This mechanism of recruitment to DNA of lineage-determining TFs is not limited to 
HPCs, as binding to H3K27-unmethylated post-replicative chromatin is also a feature of TFs 
promoting lineage-specification in mouse and human embryonic stem cells (Petruk, 2017). 
Thus, these findings of dynamic changes in chromatin conformation may provide a 
molecular explanation of the biological plasticity of hematopoietic and embryonic stem 
cells. Future studies may also provide important insights into more mechanism-based 
approaches in treatment of hematopoietic disorders including leukemia.
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Experimental Procedures
Induction of HPCs with different cytokines
Human CD34+CD38+ cells were maintained in SFEM (Stem Cell Technologies) enriched 
with CC100 cocktail of cytokines (SCF, 100 ng/ml; FLT3L, 100 ng/ml; IL-3, 20 ng/ml; IL-6, 
20 ng/ml; Stem Cell Technologies) for 12 hr after thawing. Cells were then washed to 
eliminate the CC100 cytokines and were plated at a concentration of 106 cells/ml in SFEM 
with the addition of either 100 ng/ml of G-CSF (Peprotech) or 10,000 U/ml of M-CSF 
(R&D Systems, USA) to induce myeloid differentiation, or 10 ng/ml of EPO (Peprotech) to 
induce erythroid differentiation. The cytokines were re-added at every medium-change.
Purification of CD34+CD38− HPCs
Peripheral blood human CD34+ cells mobilized by G-CSF treatment were sorted 12 hr after 
thawing on the BD FACS Aria machine, according to the expression of CD38 surface 
marker. Purified CD34+CD38− were induced to myeloid lineage with G-CSF or M-CSF and 
used in CAA and Western blotting experiments with antibodies to H3K27me3, EZH2 and 
UTX.
Purification of Lin-Sca-1+Kit+ cells
C57BL/6J mice (The Jackson Laboratory, stock number 000664) were kept in a pathogen 
free facility and euthanized in accordance with the Institutional Animal Care and Use 
Committee (IACUC) of Thomas Jefferson University. Femoral, tibial and pelvic bones of 6–
8 weeks old mice were dissected from surrounding muscles, and ground in PBS 2% FBS 
using a mortar and pestle. Bone marrow cells were filtered through a 40 μm Nylon Mesh 
Cell Strainer (Fisherbrand), and erythrocytes were lysed in 0.8% ammonium chloride 
(STEMCELLS Technologies). Cells were washed twice before staining with PerCP-Cy 5.5 
mouse lineage Antibody Cocktail (BD Pharmigen), PE Rat Anti-Mouse Ly-6A/E (Sca1, BD 
Pharmigen), FITC Rat Anti-Mouse CD117 (Kit, BD Pharmigen). Lin-Sca1+Kit+ (LSK) 
cells were sorted using a MoFlo AstriosEQ (Beckman Coulter) and then seeded at 1x106/ml 
in SFEM (STEMCELLS Technologies) supplemented with SCF (12.5 μg), FLT3L (12.5 μg), 
IL-3 (5 μg), IL-6 (5 μg), all from Gemini, for 20 hr.
Analysis of protein association with nascent DNA (CAA)
CAA experiments were performed as described before (Petruk et al., 2013; Petruk et al., 
2012) with small variations. HPCs were pulse-labeled with 5 μM EdU. Approximately 
20,000 cells per each condition were harvested and cytospun (750 rpm for 5 min) on 
polylysine-coated slides (Polyscience), fixed with 4% formaldehyde, permeabilized in 
0.25% Triton, and subjected to Click-iT reaction (Invitrogen) to conjugate biotin to EdU. 
Cells were incubated with mouse antibody to biotin and rabbit antibodies to the protein of 
interest. The PLA reaction was performed according to the manufacturer (Olink) and as 
described before. Following PLA, EdU was detected by immunostaining with Alexa Fluor 
488-conjugated anti-biotin mouse antibody.
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Re-ChIP with BrdU labeled DNA
For each experiment, 8–10x106 CD34+ peripheral blood G-CSF-mobilized cells were either 
not induced or induced for 24 hr with EPO. Undifferentiated and induced cells were labeled 
with 75 μM BrdU (Sigma-Aldrich) for 15 min or 15 min followed by chase for 2 hr and 
fixed with 1% formaldehyde for 10 min at room temperature. Chromatin was purified and 
treated with micrococcal nuclease using Simple ChIP Chromatin IP Kit (Cell Signaling). 
After treatment chromatin was immunoprecipitated first with antibody to H3K27me3 
(Millipore) or rabbit IgG (Jackson Immunoresearch). This material was analyzed as 
conventional ChIP. Following purification, DNA was further immunoprecipitated with 
antibody to BrdU and used for PCR amplification (re-ChIP). The detailed protocol is 
described in (Francis et al., 2009; Petruk et al., 2012). All PCR reactions were performed 
with an Applied Biosystems StepOne Real-Time PCR system. Genes containing H3K27me3 
at their promoters (GPR85, WNT16, HOXB8, HOXB13) and a control activated gene 
(CD11B) before and after cytokine induction were selected according to (Cui et al., 2009).
Treatment with thymidine
To control the efficiency of the thymidine block of DNA replication, CD34+CD38+ cord 
blood cells were labeled with EdU for 30 min, induced by G-CSF and grown for 24 hr in the 
presence of 2 mM thymidine. Following release from thymidine block for 2 or 4 hr, cells 
were labeled with BrdU to monitor resumption of DNA synthesis. Following ‘Click-iT’ 
reaction to conjugate biotin to EdU (Petruk et al., 2012), cell were fixed in 4% 
formaldehyde, denaturated in 2N HCL for 30min for detection of BrdU, and immunostained 
with antibodies to biotin and BrdU. To perform thymidine block analysis for recruitment of 
C/EBPα to DNA, nascent DNA of CD34+CD38+ cells was labeled for 30 min with EdU, 
cells were induced with G-CSF and grown for 24 hr in the presence of 2 mM thymidine. 
Thymidine was removed by three washes with SFEM, cells were grown for the additional 2 
or 4 hr and were cytospun on slides, fixed with 4% formaldehyde, and permeabilized in 
0.25% Triton. Following ‘Click-iT’ reaction CAA was performed between nascent DNA 
(biotin) and C/EBPα as described above.
Treatment with GSKJ4
CD34+CD38+ cells (cord blood or peripheral blood G-CSF-mobilized) were induced toward 
myeloid or erythroid differentiation for 12–72 hr in the presence of 5 μM GSKJ4 (Tocris 
Bioscience) dissolved in DMSO. In control experiments, cells were incubated with the same 
concentration of DMSO without GSKJ4. Erythroid differentiation was monitored after 72 hr 
by flow cytometry analysis detection of CD36 and glycophorin A/GYPA/CD235a double-
positive cells. Expression of GATA-1-regulated genes was analyzed at 48 hr by real time 
PCR with the following primers: GATA-1 forward 5′-GCTACACCAGGTGAACCGGC-3′, 
reverse 5′-CAGACTGGAGCCCCGTTTCT -3′; ALAS2 forward 5′-
TTCAAGACTGTGAACCGCTG -3′, reverse 5′-GCTCATGCCCAGGTAATCAT-3′, 
GYPA forward 5′-GGGTGATGGCTGGTGTTATTGG-3′, reverse 5′-
AAAGGCACGTCTGTGTCAGG-3′; ABCB10 forward 5′-
CGGAGGCCCGGAAGCTC-3′, reverse 5′-TTCCCCAGGAAGAAAGGGGC-3′.
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Granulocytic differentiation was monitored by flow cytometry analysis of CD33 and CD15 
levels (at 72 hr post-G-CSF treatment) and by expression of C/EBPα-regulated genes (at 72 
hr post G-CSF treatment) detected by real time PCR with the following primers: CEBPE (C/
EBPepsilon) forward 5′-CCAGCCGAGGCAGCTACAAT-3′, reverse 5′-
CAAAGGGGCCTTGAGAACGC-3′; MPO (myeloperoxidase) forward 5′-
TCTCCTCACCAACCGCTCAG-3′, reverse 5′-CCGGTTGTGCTCCCGAAGTA-3′; 
ELANE (neutrophilic elastase) forward 5′-CTGGGAGCCCATAACCTCTCG-3′, reverse 
5′-CGTTGAGCTGGAGAATCACGA-3′; S100A8 (calgranulin A) forward 5′-
ATATCAGGAAAAAGGGTGCAGACG-3′, reverse 5′-GCTGCCACGCCCATCTTTAT-3′. 
Real time PCR data were normalized for expression of GAPDH detected with the following 
primers forward 5′-CCCATCCCATCTTCCAGGAG-3′ and reverse 5′-
CTTCTCCATGGTGGTGAAGACG-3′.
Antibodies
Anti-human CD34-PE (Miltenyi Biotec #130-081-002) and anti-human CD38-APC 
(Miltenyi Biotec #130-092-261) were used to analyze the percentage of CD34+ and CD38+ 
populations. Anti-human CD15-PE-Cy7 (BD Pharmingen #560827), CD33-PE (BD 
Pharmingen #555450), CD11b-APC (BD Pharmingen #561015) and CD14-PE (BD 
Pharmingen #555398) were used to test the percentage of cells positive for granulocytic and 
macrophage differentiation markers; CD235a-Pe-Cy5 (BD Pharmingen #561776), CD36-PE 
(BD Pharmingen #561821) were used to assess erythroid differentiation. Cells were 
incubated with PBS + 1% BSA to prevent antibodies’ non-specific binding and then stained 
with fluorochrome-conjugated antibodies for 15 min at room temperature. Cytofluorimetric 
analysis was performed on LSRII flow cytometer (BD, USA). For CAA and 
immunostaining the following antibodies were used: anti-C/EBP (1:200, Abcam); anti-PU.1 
(1:100, Santa Cruz); anti-GATA-1 (1:400, Cell Signaling); anti-H3K27me3 (1:2500, 
Millipore); mouse anti-biotin (1:1000, Jackson Immunoresearch); UTX (1:400, Thermo 
Fisher Scientific); EZH2 (1:400, Cell Signaling); JMJD3 (1:200, Abgent); BrdU (1:200, BD 
Bioscience); CD90 (1:100, R&D System).
Statistical Analysis
For CAA experiments and re-ChiP experiment, p-values were calculated by a one-way 
ANOVA with Bonferroni’s post-hoc test. The statistical significance was defined as p<0.05.
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Figure 1. Kinetics of H3K27me3 accumulation following DNA replication in cytokine-treated 
CD34+ HPCs
(A) Left, accumulation of H3K27me3 on nascent DNA of G-CSF-mobilized CD34+ HPCs. 
DNA was labeled with EdU for 15 min and chased to 1, 2 and 4 hr. Following conjugation 
with biotin, CAA was performed between nascent DNA (biotin) and H3K27me3. PLA, red, 
EdU (biotin), green, DAPI, blue. Lower panels show PLA signals only. Right, quantification 
of the results of CAA experiments shown to the left by counting the number of PLA signals 
per EdU-labeled nuclei in 50 cells/each of the three independent experiments.
(B) Left, accumulation of post-replicative H3K27me3 during differentiation of 
CD34+HPCs. Cells were induced for myeloid differentiation with either G-CSF (upper 
panels) or M-CSF (lower panels) for 0, 6, 12 and 24 hr. DNA was labeled with EdU for 15 
min and CAA performed between EdU (biotin) and H3K27me3. PLA, red, EdU (biotin), 
green, DAPI, blue. Lower panels show PLA signals only. Right, quantification of the results 
of CAA experiments shown to the left by counting the number of PLA signals per EdU-
labeled nuclei in 50 cells/each of the three independent experiments. Error bars represent +/
− standard deviation. p Values were determined by ANOVA. ns, non-significant; *, p<0.05.
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Figure 2. Kinetics of recruitment of lineage-determining TFs C/EBPα, PU.1 and GATA-1 to DNA
(A) In vitro differentiation of G-CSF-mobilized CD34+ cells. Cells were treated with G-
CSF, M-CSF or EPO for the indicated times. Differentiation was assessed by flow cytometry 
for lineage specific markers.
(B) G-CSF-mobilized CD34+ HPCs were induced toward myeloid or erythroid 
differentiation by treatment with G-CSF, M-CSF, or EPO respectively, for 6, 12 and 24 hr. 
DNA was pulse-labeled with EdU for 15 min and chased to 1 hr. CAA was performed 
between nascent DNA (biotin) and C/EBPα, PU.1, or GATA-1. PLA, red, EdU (biotin), 
green, DAPI, blue. Lower panel shows PLA signals only. Bottom, quantification of the 
results of CAA experiments shown above by counting the number of PLA signals per EdU-
labeled nuclei in 50 cells/each of the three independent experiments. Error bars represent +/
− standard deviation. p Values were determined by ANOVA. *, p<0.05.
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Figure 3. H3K27me3-unmodified post-replicative chromatin is essential for DNA binding of 
lineage-determining TFs
(A) Top, accumulation of post-replicative H3K27me3 leads to decreased recruitment of 
lineage-determining TFs. Cord blood CD34+ cells were induced toward myeloid 
differentiation with G-CSF (left) or M-CSF (middle), or erythroid differentiation with EPO 
(right) for 12 hr. During the induction period cells were left untreated (upper panels) or 
treated with the GSKJ4 inhibitor of KDMs UTX and JMJD3 (lower panels). DNA was 
pulse-labeled with EdU for 15 min and chased to 1 hr. CAA was performed between nascent 
DNA (biotin) and C/EBPα (left), PU.1 (middle) or GATA-1 (right). PLA, red, EdU (biotin), 
green, DAPI, blue. Lower panel shows PLA signals only. Bottom, quantification of the 
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results of CAA experiments shown above by counting the number of PLA signals per EdU-
labeled nuclei in 50 cells/each of the three independent experiments.
(B, C) G-CSF-mobilized CD34+ cells were cultured for 24 h in the presence of the CC100 
cytokine cocktail (CTRL), or with EPO only (EPO) or with EPO and GSKJ4 (EPO
+GSKJ4). B, Cells were immunostained with antibody to GATA-1 (red). DAPI, blue. Lower 
panel shows GATA-1 signals only. C, Western blot analysis with GATA1 and Actin 
antibodies
(D, E) Effect of UTX/JMJD3 inhibition on EPO-induced erythroid differentiation of CD34+ 
HPCs. Cells were cultured for 72 hr in the presence of the CC100 cytokine cocktail (CTRL), 
or in the presence of EPO only (EPO) or in the presence of EPO only and GSKJ4 (EPO + 
GSKJ4). D, real time PCR analysis (performed in triplicate) of GATA-1 target genes in 
untreated, EPO-, or EPO plus GSKJ4-treated CD34+CD38+ cells; E, erythroid 
differentiation monitored by flow cytometry. Error bars represent +/− standard deviation. p 
Values were determined by Student’s T test. ***, p<0.001.
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Figure 4. C/EBPα is recruited to DNA only during post-replicative period
(A) Cord blood CD34+ HPCs were labeled with EdU for 30 min and induced with G-CSF 
for 24 hr in the absence (Cont) or presence of 2.5 mM thymidine. After release from 
thymidine block, CAA was performed between nascent DNA (biotin) and C/EBPα at 0, 2 
and 4 hr. PLA, red, EdU (biotin), green, DAPI, blue. Lower panel shows PLA signals only. 
A graph below shows quantification of the results of CAA experiments by counting the 
number of PLA signals per EdU-labeled nuclei in 50 cells/each of the three independent 
experiments.
(B) Following DNA labeling with EdU for 30 min and induction with G-CSF, CD34+ HPCs 
were grown for 24 hr in the presence of thymidine. Thymidine block was released for 0, 2 
and 4 hr, and cells were labeled for 20 min with BrdU. Cells were double-immunostained 
for EdU (green) and BrdU (red). Error bars represent +/− standard deviation. p Values were 
determined by ANOVA. *, p<0.05.
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Figure 5. H3K27me3-conatining nascent chromatin undergoes dynamic changes in cytokine-
treated primitive HPCs
(A) CD34+ HPCs were labeled with EdU for 15 min. CAA was performed for H3K27me3 
antibody. Cells were then immunostained for CD90 (green) and EdU (blue).
(B) Induction of CD34+CD38− HPCs with G-CSF (top) or M-CSF (bottom) leads to de-
methylation of H3K27me3. Purified CD34+CD38− HPCs were induced with G-CSF (upper 
panels) or M-CSF (lower panels) for 0, 12 and 24 hr. Cells were labeled with EdU for 15 
min. CAA was performed between nascent DNA (biotin) and H3K27me3 antibodies. PLA, 
red, EdU (biotin), green, DAPI, blue. Lower panel shows PLA signals only. Quantification 
of the results of CAA experiments is shown under images and was estimated by counting the 
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number of PLA signals per EdU-labeled nuclei in 50 cells/each of the three independent 
experiments. Error bars represent +/− standard deviation. p Values were determined by 
ANOVA. *, p<0.05.
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Figure 6. Kinetics of H3K27me3 accumulation at nascent DNA of specific genes during erythroid 
differentiation of CD34+ HPCs
(A) ChIP assays with the H3K27me3 antibody. Uninduced and 24 hr EPO-induced CD34+ 
cells were labeled with BrdU for 15 min or 15 min and chased to 60 min. Chromatin was 
immunoprecipitated with H3K27me3 and IgG antibodies.
(B) ChIP assays with the BrdU antibody. DNA from the first immunoprecipitation step with 
H3K27me3 antibody (A) was denatured and immunoprecipitated with the BrdU antibody. 
Q-PCR was performed at genes repressed before and after EPO induction (GPR85, WNT16, 
HOXB8, HOXB13) and at a non-repressed control gene (CD11B) (Cui et al., 2009). Percent 
of input for re-ChIP experiments was calculated using the amount of material eluted from 
the beads following immunoprecipitation with H3K27me3 as 100% input. Data are 
represented as mean ± SD of technical replicates of one of the independent experiments. p-
values were calculated by a one-way ANOVA with Bonferroni’s post-hoc test. The statistical 
significance was defined as p<0.05.
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Figure 7. Induction of H3K27me3 KDMs UTX and JMJD3 during lineage specification
(A) Kinetics of EZH2 (left panels) panels and UTX (right panels) accumulation during 
induction of CD34+CD38− HPCs with G-CSF (upper panels) or M-CSF (lower panels). 
Purified CD34+CD38− HPCs were induced with G-CSF (left) or M-CSF (right) for 0 and 12 
hr. Cells were labeled with EdU for 15 min and chased to 1 hr. CAA was performed between 
nascent DNA (biotin) and EZH2 (upper panels) or UTX (lower panel) antibodies. PLA, red, 
EdU (biotin), green, DAPI, blue. Lower panel shows PLA signals only. Graphs represent 
quantification of the results of CAA experiments shown above by counting the number of 
PLA signals per EdU-labeled nuclei in 50 cells/each of the three independent experiments. 
Error bars represent +/− standard deviation. p Values were determined by ANOVA. *, 
p<0.05.
(B) CD34+CD38− or CD34+CD38+ HPCs were uninduced or induced by treatment with G-
CSF or M-CSF. Cells were analyzed by Western blotting with antibody to UTX protein.
(C) CD34+ HPCs were immunostained with antibodies to UTX (red), CD90 (green, 
indicated by arrows) and EZH2 (blue).
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(D) CD34+ HPCs were pulse-labeled with EdU for 1 hr. CAA was performed for UTX and 
JMJD3 antibodies and EdU (biotin). Cells were then immunostained for CD90 (green, 
indicated by arrows) and EdU (blue).
(E) A model for opening of post-replicative chromatin and recruitment of TFs to nascent 
DNA upon induction of primitive HPCs with lineage-specific cytokines. Primitive 
(CD34+CD38− or CD34+CD90+) HPCs exhibit the H3K27me3 repressive mark on post-
replicative chromatin; treatment with instructive cytokines induces H3K27me3 demethylase 
activity (UTX in the model) and expression of lineage-determining TFs. H3K27me3-
unmodified post-replicative chromatin allows binding of lineage-determining TFs to nascent 
DNA. Upon commitment to unilineage differentiation, H3K27me3 accumulates fast on 
nascent DNA preventing binding of additional TFs thus restricting transcriptional program 
and differentiation potential of these cells.
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